Hikma Confirms Share Capital and Voting Rights for Disclosure Purposes

Hikma Pharmaceuticals ( (GB:HIK) ) has provided an announcement.

Hikma Pharmaceuticals has confirmed that, as of 30 April 2026, its issued share capital consists of 216,634,000 ordinary shares of 10 pence each carrying voting rights, excluding 12,833,233 treasury shares without voting rights. The company noted that the 216,634,000 figure should be used by shareholders and other market participants as the denominator when calculating disclosure thresholds for holdings under UK financial transparency rules, ensuring accurate reporting of significant shareholdings and changes in ownership.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £1800.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

Spark’s Take on HIK Stock

According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.

The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.

To see Spark’s full report on HIK stock, click here.

More about Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC is a London-listed pharmaceutical company operating in the healthcare sector. The company issues ordinary shares with voting rights and maintains a portion of its stock in treasury, which does not carry voting power, in line with standard UK corporate governance practices.

Average Trading Volume: 1,402,474

Technical Sentiment Signal: Sell

Current Market Cap: £3.01B

For an in-depth examination of HIK stock, go to TipRanks’ Overview page.